Biomea Fusion Inc

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

REDWOOD CITY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, presented preclinical data today for BMF-500, an investigational covalent FLT3 inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting. The preclinical poster can be viewed at Biomea's website at https://biomeafusion.com/publications.

Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date

REDWOOD CITY, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”)(Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that Biomea's management will participate in a fireside chat and host investor meetings at the upcoming Piper Sandler 34th Annual Healthcare Conference.

Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference

REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, reported third quarter 2022 financial results and business highlights.

Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights

REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced it will present preclinical data of investigational covalent FLT3 inhibitor, BMF-500, at the 64th ASH Annual Meeting, which will be held from December 10-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting

REDWOOD CITY, Calif., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared Biomea's IND application to begin a Phase I/Ib trial of BMF-219, a selective, covalent menin inhibitor in patients with unresectable, locally advanced, or metastatic NSCLC, CRC, and PDAC with an activating KRAS mutation.

BMF-219 Enters the Clinic for KRAS Solid Tumors

REDWOOD CITY, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, presented “Oral long-acting menin inhibitor normalizes type 2 diabetes in two rat models” at the European Association for the Study of Diabetes Annual Meeting (EASD).

Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in Animal Models and Ex-vivo Human Donor Islets Further Supporting BMF-219's Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

REDWOOD CITY, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, presented today “Oral menin inhibitor, BMF-219, displays a significant and durable reduction in HbA1c in a type 2 diabetes rat model", the first of two oral presentations at the EASD Annual Meeting.

Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219's Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes

REDWOOD CITY, Calif., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced today the presentation of two posters at the 19th International Myeloma Society (IMS) Annual Meeting, which took place August 25-27, 2022 in Los Angeles, California. Both poster presentations can be viewed on Biomea's website at https://biomeafusion.com/publications.

Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual Meeting

REDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, reported second quarter 2022 financial results and business highlights.

Biomea Fusion Reports Second Quarter 2022 Financial Results and Business Highlights

REDWOOD CITY, Calif., July 01, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced today that two BMF-219 preclinical abstracts were chosen for oral presentations at the European Association for the Study of Diabetes (EASD) Annual Meeting. The EASD, one of the largest networks for diabetologists worldwide, holds its Annual Meeting in a different European city each year with more than 15,000 delegates from over 130 countries attending. This year's 58th EASD Annual Meeting will be held in Stockholm, Sweden, 19 - 23 September 2022.

Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219's Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes

REDWOOD CITY, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), today announced that the first patient has been dosed in the MM cohort of COVALENT-101, the company's Phase I clinical trial evaluating BMF-219, Biomea's covalent menin inhibitor, in patients with R/R AML, ALL, DLBCL, and MM.

Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial

REDWOOD CITY, Calif., June 04, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, presented new data at the American Diabetes Association (ADA) Scientific Sessions demonstrating BMF-219's strong, prolonged glycemic control, insulin sensitization, and HbA1c reduction in two preclinical rat models of diabetes. These data suggest BMF-219's potential as an oral, long-acting treatment for type 2 diabetes. The preclinical presentations can be viewed on Biomea's website at  https://biomeafusion.com/publications .

Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219's Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

REDWOOD CITY, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced that Thomas Butler, Chief Executive Officer and Chairman of the Board, will participate in a fireside chat and meet with investors at the in-person Jefferies Healthcare Conference. The fireside chat will take place on Wednesday, June 8th at 2:30pm Eastern Time.

Biomea Fusion to Participate in Jefferies Healthcare Conference

REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced it will present new data at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating BMF-219's activity in ex vivo preclinical models of CLL. In addition, the company will present a Trial In Progress (TIP) poster presentation detailing the design of COVALENT-101. Once released at the ASCO Annual Meeting, the preclinical and TIP presentations can be viewed on Biomea's website at  https://biomeafusion.com/publications .

Biomea Fusion to Present New Preclinical Data Showing BMF-219's Strong Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022

REDWOOD CITY, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced that Biomea will attend the H.C. Wainwright Global Investment Conference virtually and will participate in 1x1 meetings held by the conference organizers.

Biomea Fusion to Attend H.C. Wainwright Global Investment Conference

REDWOOD CITY, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, reported first quarter 2022 financial results and business highlights.

Biomea Fusion Reports First Quarter 2022 Financial Results and Business Highlights

REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced that Thomas Butler, Chief Executive Officer and Chairman of the Board, will participate in a fireside chat at the live Bank of America Securities 2022 Healthcare Conference. The fireside chat will take place on Wednesday, May 11th at 4:00pm Pacific Time.

Biomea Fusion to Participate in Bank of America Securities 2022 Healthcare Conference

REDWOOD CITY, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced the acceptance of two abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The 2022 ASCO annual meeting will be held from June 3-7, 2022, at McCormick Place in Chicago, IL.

Biomea Fusion Announces Acceptance of Multiple Abstracts at the 2022 ASCO Annual Meeting

REDWOOD CITY, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today presented new data at the American Association of Cancer Research (AACR) Annual Meeting demonstrating BMF-219's potent and highly effective activity in multiple preclinical models of DLBCL, MM, and KRAS human ex vivo tumor models and cell lines in poster presentations. In addition, the company presented a Trial In Progress (TIP) poster presentation detailing the design of Biomea's ongoing Phase I clinical trial (COVALENT-101).

Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting

REDWOOD CITY, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that a late breaking abstract has been accepted at the upcoming American Diabetes Association (ADA) 82nd Scientific Sessions. The ADA 82nd Scientific Sessions will be held from June 3-7, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.

Biomea Fusion Announces Acceptance of Late Breaking Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022

REDWOOD CITY, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that it is scheduled to participate in a fireside chat at the Oppenheimer 32nd Annual Virtual Healthcare Conference on Wednesday, March 16, 2022 at 7:00am Pacific Time. Thomas Butler, Biomea's CEO and Chairman of the Board, will participate in the fireside chat.

Biomea Fusion to Present at Oppenheimer's 32nd Annual Virtual Healthcare Conference

REDWOOD CITY, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that an abstract has been accepted at the upcoming American Diabetes Association (ADA) 82nd Scientific Sessions. The ADA 82nd Scientific Sessions will be held from June 3-7, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.

Biomea Fusion Announces Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022

REDWOOD CITY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that two abstracts on BMF-219 have been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022. The AACR Annual Meeting will be held from April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA. BMF-219, Biomea's lead program, is an irreversible covalent menin inhibitor, currently in a Phase I study for the treatment of patients with relapsed/refractory acute leukemias, including those with the MLL1/KMT2A gene rearrangements and NPM1 mutations. BMF-219 is the first and only irreversible covalent menin inhibitor in the clinic.

Biomea Fusion Announces Upcoming Presentations of Preclinical Data in Diffuse Large B-Cell Lymphoma, Multiple Myeloma, and Several KRAS Mutant Solid Tumors for BMF-219 at AACR Annual Meeting 2022

REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, reported fourth quarter and full year 2021 financial results and business highlights.

Biomea Fusion Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

Biomea Fusion (BMEA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

News for Biomea Fusion Inc Stock (BMEA)